ACCESS Newswire·Mar 26, 2026, 8:05 AM ET

Aptevo Provides State of the Business Report and 2025 Financial Results

APVO

Aptevo Therapeutics reported mipletamig data showing an 86% clinical benefit rate in 28 frontline AML patients with no observed cytokine release syndrome.
The mipletamig triplet regimen achieved a 79% CR/CRi rate and a 61% complete remission rate, compared to historical ven/aza doublet rates of 66% and 37%.
55% of patients achieving remission reached measurable residual disease-negative status, including 35% of those with high-risk TP53 mutations.
Four patients treated with mipletamig proceeded to allogeneic stem cell transplant, a notable outcome for older or unfit frontline populations.
The company expanded its CD3 portfolio with three new multispecific candidates, including its first two trispecific drug assets designed for solid tumors.
All pipeline programs utilize the proprietary CRIS-7-derived CD3 binding domain to promote targeted T-cell activation while reducing systemic immune overstimulation.
Aptevo established a $60 million equity line facility with Yorkville Advisors Global in 2026 to support operations through 2029.
Cash and cash equivalents totaled $21.6 million as of December 31, 2025, up from $8.7 million in the prior year.
Research and development expenses were $14.5 million for 2025, while general and administrative expenses rose to $11.8 million.
The company reported a net loss of $26.0 million for 2025, resulting in a net loss per share of $87.27.
Marvin White is transitioning to Executive Chair while Jeff Lamothe assumes the role of President and Chief Executive Officer.
Mipletamig has received orphan drug designation for AML and is being evaluated in the RAINIER Phase 1b/2 trial in combination with venetoclax and azacitidine.